| Literature DB >> 30854122 |
Chao Kang1, Jianwu Zhao2, Yuanchun Wang3, Chenguang Yang1, Jie Chen1, Liqiang Zhi4.
Abstract
Osteosarcoma (OS) is one of the most common malignant bone tumors. Many previous studies have indicated that OS is a complex disease and that its development may be affected by multiple genetic factors, which may contribute to its carcinogenesis. The aim of the present study was to evaluate the relationship of IL-33 with susceptibility and prognosis of OS in Han Chinese individuals. A total of 1,605 study subjects including 507 OS patients and 1,098 controls were recruited. Eighteen SNPs mapped to IL-33 were selected for genotyping. Genetic associations between selected SNPs and OS disease status were evaluated. Survival analyses, including Kaplan-Meier analysis and Cox model fitting for significant SNPs, were performed. The functional consequences of significant SNPs were analyzed using a publicly available database. SNP rs1048274 was identified to be significantly associated with OS disease status (OR=0.75, P=1.53×10-4). Compared to the GA and GG groups, OS patients with the AA genotype of rs1048274 had better survival rate. The hazard ratio of SNP rs1048274 (AA group compared to GG+GA group) was 0.35 (95% confidence interval of 0.25-0.5) following adjustment for several clinical variables. In conclusion, our results suggested that IL-33 may play a key role in the etiology of OS, indicating IL-33 as a potential genetic risk factor of the development and prognosis of OS.Entities:
Keywords: Case-control studies; Common variants; IL-33; Osteosarcoma susceptibility; Prognosis
Year: 2019 PMID: 30854122 PMCID: PMC6400670 DOI: 10.7150/jca.29086
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Distributions of selected variables in all subjects
| Variables | Subjects (N=1605) | Statistics | ||
|---|---|---|---|---|
| OS (N=507) | Control (N=1098) | |||
| Mean age, years (%) | 21.08±6.1 | 21.12±5.8 | 0.90 | |
| ≤20 | 318 (62.7) | 700 (63.8) | ||
| >20 | 189 (37.3) | 398 (36.2) | χ2=0.12 | 0.73 |
| Gender (%) | ||||
| Male | 261 (51.5) | 563 (51.3) | ||
| Female | 246 (48.5) | 535 (48.7) | χ2= 0.0005 | 0.98 |
| Cancer family history (%) | ||||
| Yes | 158 (31.2) | 333 (30.3) | ||
| No | 349 (68.8) | 765 (69.7) | χ2= 0.08 | 0.78 |
| Tumor location (%) | ||||
| Long tubular bones | 408 (80.5) | - | ||
| Axial skeleton | 99 (19.5) | - | - | - |
| Pathological fracture (%) | ||||
| Yes | 87 (17.2) | - | ||
| No | 420 (82.8) | - | - | - |
| Metastasis (%) | ||||
| Yes | 112 (22.1) | - | ||
| No | 395 (77.9) | - | - | - |
| Enneking stages (%) | ||||
| I | 47 (9.3) | - | ||
| II | 391 (77.1) | - | ||
| III | 69 (13.6) | - | - | - |
Results of single marker based association analyses
| CHR | SNP | POS | A1 | F_A | F_U | χ2 | OR | |
|---|---|---|---|---|---|---|---|---|
| 9 | rs1157505 | 6216240 | G | 0.265 | 0.262 | 0.043 | 0.84 | 1.02 |
| 9 | rs11791561 | 6216516 | C | 0.449 | 0.453 | 0.054 | 0.82 | 0.98 |
| 9 | rs72614080 | 6218595 | T | 0.274 | 0.279 | 0.071 | 0.79 | 0.98 |
| 9 | rs1891385 | 6219845 | C | 0.223 | 0.226 | 0.035 | 0.85 | 0.98 |
| 9 | rs143589217 | 6220187 | A | 0.048 | 0.047 | 0.031 | 0.86 | 1.03 |
| 9 | rs16924144 | 6221246 | C | 0.314 | 0.317 | 0.036 | 0.85 | 0.98 |
| 9 | rs183791076 | 6222545 | G | 0.052 | 0.053 | 0.004 | 0.95 | 0.99 |
| 9 | rs10975495 | 6223819 | A | 0.057 | 0.055 | 0.086 | 0.77 | 1.05 |
| 9 | rs1418385 | 6226295 | T | 0.476 | 0.472 | 0.058 | 0.81 | 1.02 |
| 9 | rs16924159 | 6229417 | A | 0.298 | 0.293 | 0.084 | 0.77 | 1.02 |
| 9 | rs189217453 | 6230731 | T | 0.050 | 0.048 | 0.092 | 0.76 | 1.06 |
| 9 | rs182211245 | 6230736 | C | 0.050 | 0.051 | 0.019 | 0.89 | 0.98 |
| 9 | rs117414011 | 6242939 | C | 0.071 | 0.076 | 0.256 | 0.61 | 0.93 |
| 9 | rs4742170 | 6242950 | C | 0.487 | 0.482 | 0.068 | 0.79 | 1.02 |
| 9 | rs79981454 | 6247232 | C | 0.042 | 0.038 | 0.391 | 0.53 | 1.13 |
| 9 | rs76864631 | 6248408 | A | 0.248 | 0.242 | 0.124 | 0.73 | 1.03 |
| 9 | rs10758751 | 6252044 | C | 0.074 | 0.077 | 0.064 | 0.80 | 0.96 |
POS: position; A1: tested allele; F_A: allele frequency in cases; F_U: allele frequency in controls. Threshold of P value was 0.0028 (0.05/18). Significant results were highlighted in bold.
Association between genotypes of rs1048274 and several clinical variables within our OS subjects
| Genotypes of rs1048274 (N=507) | Statistics | ||||
|---|---|---|---|---|---|
| AA (N=83) | AG (N=254) | GG (N=170) | |||
| Age in years, mean±sd | 20.6±5.8 | 21.4±6.2 | 20.8±6.0 | 0.87 | |
| Gender (%) | |||||
| Male (N=261) | 43 (16.5) | 130 (49.8) | 88 (33.7) | ||
| Female (N=246) | 40 (16.3) | 124 (50.4) | 82 (33.3) | χ2=0.02 | 0.99 |
| Tumor location (%) | |||||
| Long tubular bones (N=408) | 62 (15.2) | 209 (51.2) | 137 (33.6) | ||
| Axial skeleton (N=99) | 21 (21.2) | 45 (45.5) | 33 (33.3) | χ2=2.29 | 0.32 |
| Pathological fracture (%) | |||||
| Yes (N=87) | 13 (14.9) | 47 (54.0) | 27 (31.1) | ||
| No (N=420) | 70 (16.7) | 207 (49.3) | 143 (34.0) | χ2=0.65 | 0.72 |
| Metastasis (%) | |||||
| Yes (N=112) | 18 (16.1) | 55 (49.1) | 39 (34.8) | ||
| No (N=395) | 65 (16.5) | 199 (50.4) | 131 (33.1) | χ2=0.11 | 0.95 |
| Enneking stages (%) | |||||
| I (N=47) | 11 (23.4) | 23 (48.9) | 13 (27.7) | ||
| II (N=391) | 58 (14.8) | 199 (50.9) | 134 (34.3) | ||
| III (N=69) | 14 (20.3) | 32 (46.4) | 23 (33.3) | χ2=3.43 | 0.49 |
Figure 1Kaplan-Meier analysis and survival plot for the overall survival of OS patients with different genotypes of s1048274. P values for Kaplan-Meier analysis are indicated on the plot.
Figure 2Forest plot for the survival analysis of rs1048274 using a Cox model after adjustment for multiple clinical variables.